Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2022 Mar 1;5(3):e222940.
doi: 10.1001/jamanetworkopen.2022.2940.

Incidence of Cerebral Venous Thrombosis Following SARS-CoV-2 Infection vs mRNA SARS-CoV-2 Vaccination in Singapore

Tian Ming Tu  1 , Shen Jia Yi  1 , Jasmine Shimin Koh  1 , Seyed Ehsan Saffari  2   1 , Rebecca Hui Min Hoe  1 , Geraldine Jiangyan Chen  3 , Hui Jin Chiew  1 , Carol Huilian Tham  1 , Christopher Ying Hao Seet  1 , Ming Hui Yong  1 , Kok Pin Yong  1 , Andrew Che-Fai Hui  1 , Bingwen Eugene Fan  4 , Benjamin Yong-Qiang Tan  5 , Amy May Lin Quek  5 , Raymond Chee Seong Seet  5 , Leonard Leong Litt Yeo  5 , Kevin Tan  1 , Umapathi N Thirugnanam  1
Affiliations
Observational Study

Incidence of Cerebral Venous Thrombosis Following SARS-CoV-2 Infection vs mRNA SARS-CoV-2 Vaccination in Singapore

Tian Ming Tu et al. JAMA Netw Open. .

Abstract

Importance: Reports of cerebral venous thrombosis (CVT) after messenger RNA (mRNA)-based SARS-CoV-2 vaccination has caused safety concerns, but CVT is also known to occur after SARS-CoV-2 infection. Comparing the relative incidence of CVT after infection vs vaccination may provide a better perspective of this complication.

Objective: To compare the incidence rates and clinical characteristics of CVT following either SARS-CoV-2 infection or mRNA-based SARS-CoV-2 vaccines.

Design, setting, and participants: Between January 23, 2020, and August 3, 2021, this observational cohort study was conducted at all public acute hospitals in Singapore, where patients hospitalized with CVT within 6 weeks of SARS-CoV-2 infection or after mRNA-based SARS-CoV-2 vaccination (BNT162b2 [Pfizer-BioNTech] or mRNA-1273 [Moderna]) were identified. Diagnosis of SARS-CoV-2 infection was based on quantitative reverse transcription-polymerase chain reaction or positive serology. National SARS-CoV-2 infection data were obtained from the National Centre for Infectious Disease, Singapore, and vaccination data were obtained from the National Immunisation Registry, Singapore.

Exposures: SARS-CoV-2 infection or mRNA-based SARS-CoV-2 vaccines.

Main outcomes and measures: Clinical characteristics, crude incidence rate (IR), and incidence rate ratio (IRR) of CVT after SARS-CoV-2 infection and after mRNA SARS-CoV-2 vaccination.

Results: Among 62 447 individuals diagnosed with SARS-CoV-2 infections included in this study, 58 989 (94.5%) were male; the median (range) age was 34 (0-102) years; 6 CVT cases were identified (all were male; median [range] age was 33.5 [27-40] years). Among 3 006 662 individuals who received at least 1 dose of mRNA-based SARS-CoV-2 vaccine, 1 626 623 (54.1%) were male; the median (range) age was 50 (12-121) years; 9 CVT cases were identified (7 male individuals [77.8%]; median [range] age: 60 [46-76] years). The crude IR of CVT after SARS-CoV-2 infections was 83.3 per 100 000 person-years (95% CI, 30.6-181.2 per 100 000 person-years) and 2.59 per 100 000 person-years (95% CI, 1.19-4.92 per 100 000 person-years) after mRNA-based SARS-CoV-2 vaccination. Six (66.7%) received BNT162b2 (Pfizer-BioNTech) vaccine and 3 (33.3%) received mRNA-1273 (Moderna) vaccine. The crude IRR of CVT hospitalizations with SARS-CoV-2 infection compared with those who received mRNA SARS-CoV-2 vaccination was 32.1 (95% CI, 9.40-101; P < .001).

Conclusions and relevance: The incidence rate of CVT after SARS-CoV-2 infection was significantly higher compared with after mRNA-based SARS-CoV-2 vaccination. CVT remained rare after mRNA-based SARS-CoV-2 vaccines, reinforcing its safety.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Tu reported being a member of the neurology expert panel for the Singapore Health Sciences Authority advising on thrombotic events related to COVID-19 vaccines. Dr Yeo reported receiving Cereflo shares and grants from NMRC outside the submitted work. Dr K. Tan reported receiving personal fees from Novartis, Merck, Sanofi, Eisai, Viela Bio, and Roche outside the submitted work. No other disclosures were reported.

References

    1. Tu TM, Goh C, Tan YK, et al. . Cerebral venous thrombosis in patients with COVID-19 infection: a case series and systematic review. J Stroke Cerebrovasc Dis. 2020;29(12):105379. doi:10.1016/j.jstrokecerebrovasdis.2020.105379 - DOI - PMC - PubMed
    1. Hameed S, Wasay M, Soomro BA, et al. . Cerebral venous thrombosis associated with COVID-19 infection: an observational, multicenter study. Cerebrovasc Dis Extra. 2021;11(2):55-60. doi:10.1159/000516641 - DOI - PMC - PubMed
    1. Koh JS, De Silva DA, Quek AML, et al. . Neurology of COVID-19 in Singapore. J Neurol Sci. 2020;418:117118. doi:10.1016/j.jns.2020.117118 - DOI - PMC - PubMed
    1. Al-Mufti F, Amuluru K, Sahni R, et al. . Cerebral venous thrombosis in COVID-19: a New York metropolitan cohort study. AJNR Am J Neuroradiol. 2021;42(7):1196-1200. doi:10.3174/ajnr.A7134 - DOI - PMC - PubMed
    1. Haas EJ, Angulo FJ, McLaughlin JM, et al. . Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397(10287):1819-1829. doi:10.1016/S0140-6736(21)00947-8 - DOI - PMC - PubMed

Publication types

MeSH terms